Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H28N2O3 |
| Molecular Weight | 332.4372 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(O)C(C)=C2CC[C@](C)(OC2=C1C)C(=O)N[C@@H]3CCCNC3
InChI
InChIKey=LZYWLEPSQNXESC-KUHUBIRLSA-N
InChI=1S/C19H28N2O3/c1-11-12(2)17-15(13(3)16(11)22)7-8-19(4,24-17)18(23)21-14-6-5-9-20-10-14/h14,20,22H,5-10H2,1-4H3,(H,21,23)/t14-,19+/m1/s1
| Molecular Formula | C19H28N2O3 |
| Molecular Weight | 332.4372 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:13:21 UTC 2023
by
admin
on
Sat Dec 16 09:13:21 UTC 2023
|
| Record UNII |
JCU3O35RDS
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C170380
Created by
admin on Sat Dec 16 09:13:21 UTC 2023 , Edited by admin on Sat Dec 16 09:13:21 UTC 2023
|
PRIMARY | |||
|
100000181147
Created by
admin on Sat Dec 16 09:13:21 UTC 2023 , Edited by admin on Sat Dec 16 09:13:21 UTC 2023
|
PRIMARY | |||
|
72710875
Created by
admin on Sat Dec 16 09:13:21 UTC 2023 , Edited by admin on Sat Dec 16 09:13:21 UTC 2023
|
PRIMARY | |||
|
1541170-75-5
Created by
admin on Sat Dec 16 09:13:21 UTC 2023 , Edited by admin on Sat Dec 16 09:13:21 UTC 2023
|
PRIMARY | |||
|
JCU3O35RDS
Created by
admin on Sat Dec 16 09:13:21 UTC 2023 , Edited by admin on Sat Dec 16 09:13:21 UTC 2023
|
PRIMARY | |||
|
10972
Created by
admin on Sat Dec 16 09:13:21 UTC 2023 , Edited by admin on Sat Dec 16 09:13:21 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> DERIVATIVE |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Mechanism of Action: Reactive oxygen species modulators; Orphan Drug Status: Yes for MELAS syndrome, Leigh disease, Mitochondrial disorders; On Fast track: No; New Molecular Entity: Yes; Highest Development Phases: Phase I for Mitochondrial disorders, Preclinical for Parkinson's disease; Most Recent Events: 10 Aug 2015 KH 176 receives Orphan Drug status for MELAS syndrome in European Union, 01 May 2015 Phase-I clinical trials in Mitochondrial disorders (In volunteers) in Belgium (PO) (NCT02544217), 01 May 2015 Preclinical trials in Parkinson's disease in Netherlands (PO)
|
